Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Specialties
Farmaceutico - Biotecnologie
New hires at Alexion Pharmaceuticals
-
-
-
Global Equity Plan Manager
Came from...
EquityComp Associates, LLC, Director, Business Operations
-
Coordinator, Corporate Communications
Came from...
Focus Group Solutions, Inc., Director, Federal Research & Communications
-
Alexion Pharmaceuticals Activity on LinkedIn
-
Alexion Pharmaceuticals has a new Manufacturing Associate II
Abedin Koshi is now Manufacturing Associate II
-
-
-
-
-
Alexion Pharmaceuticals has a new Senior Exeutive - Accounting
Shiju Samuel is now Senior Exeutive - Accounting
-
-
-
-
